Hello,
Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board.
Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox.
You’re just two quick steps away from completing your sign-up:
1. Make sure our emails go to your inbox
Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary
Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP
Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts
2. Confirm your subscription
Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter.
Confirm your subscription here.
After you confirm, feel free to download our popular free report, “7 Stocks to Buy and Hold Forever” with this link.
Thanks again for subscribing—we look forward to being part of your investing journey.

Matthew Paulson
Founder and CEO, MarketBeat.
P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Today’s Exclusive Article
Phreesia Hits Bottom in Q1: Rebound Ahead, Timing Uncertain
Authored by Thomas Hughes. Article Published: 4/2/2026.
Key Points
- Phreesia is well-positioned as a growing health-oriented fintech, providing patient intake and payment services.
- Reduced guidance sparked market capitulation, with retail investors bowing out, leaving the stock at rock-bottom prices as Q1 2026 ended.
- Analysts’ revisions aided the downdraft; institutional trends suggest they bought the stock, providing a floor for Q2.
- Special Report: Elon’s “Hidden” Company
For years, Phreesia, Inc. (NYSE: PHR) has seen its stock price struggle. Those challenges aren’t entirely the company’s fault; they’ve largely resulted from rapid growth that was funded through share issuance and debt. As Phreesia has acquired new technology and expanded its offerings, its share count has risen significantly since 2024. And despite the stock losing nearly 50% in Q1 2026, market capitulation after Phreesia’s 2026 guidance update created a deep-value opportunity in a quality healthcare‑tech speculation.
Phreesia provides automated patient intake services for healthcare providers, is growing at a robust pace, and has moved to sustained profitability. That profitability underpins the stock’s outlook and offers visible value for investors.
Phreesia Growth Outlook Underestimates Potential
Navellier Warns: This Could Leapfrog Elon’s SpaceX IPO (Ad)
Navellier Warns: This Could Leapfrog Elon’s SpaceX IPO
Elon Musk could take SpaceX public in 2026, at an estimated $1.75 trillion valuation. The IPO would include Elon’s AI model, Grok. But according to Louis Navellier, a radical new AI model will launch this year… over 1,000 times more powerful than Elon’s. And the company behind it could outperform SpaceX in the process.Click here for full details (including Louis’ new pick — free).
Healthcare trends suggest Phreesia’s revenue growth outlook is conservative. The industry is undergoing an industry‑wide overhaul — digitization, broader artificial intelligence adoption and workflow automation are all accelerating.
Analysts expect the total addressable market to roughly double over the next eight years, which should support growth well above the company’s current conservative projections. While management has guided to low single‑digit growth, Phreesia’s market exposure suggests it could exceed that expected compound annual growth rate over time.
Catalysts for 2026 include integrating AccessOne, a health‑focused fintech that provides flexible patient payment solutions. AccessOne should expand Phreesia’s client base and payment capabilities and is expected to account for more than 25% of the company’s payment processing volume by 2028. Management signaled on the most recent earnings callthat it will increase spending to accelerate the acquisition’s rollout, and AccessOne may not be the last acquisition.
The impact on the company’s balance sheet is clear. Debt increased and cash declined following the deal, but those changes were partially offset by growth in assets, revenue and cash flow. Shareholders’ equity also rose, which could provide upside if leverage is reduced. The company remains adequately capitalized, though additional acquisitions could increase funding needs.
Phreesia Had a Strong Quarter, but Visibility Limits Upside in Early 2026
Phreesia delivered a solid quarter to close fiscal 2026. Net revenue was $127.07 million, up nearly 16% year over year and above expectations. Revenue growth was driven by a 7% increase in clients and an 8% increase in revenue per client — encouraging signs for upcoming quarters.
Margins were the main concern, though not as dire as the nearly 30% post‑release share‑price plunge implied. The company remained profitable for a third consecutive quarter but missed EPS estimates, reporting $0.02 per share (about $0.04 below consensus). Other metrics were stronger: free cash flow (FCF) was $28.5 million, up more than 200%, and management expects FCF to remain healthy.
Guidance and analysts’ reactions explain why the market sold off. Phreesia lowered its revenue outlook because of reduced visibility, prompting analysts to cut price targets. The likely path is improving visibility as the fiscal first half progresses, which should firm the outlook and improve sentiment.
MarketBeat tracked multiple price‑target reductions that point to a low‑end range around $10 — roughly 25% upside from the post‑release lows.
Phreesia Hits Bottom: Institutional Buyers Drive Volume
The post‑release price action was ugly, but it supports the thesis that the stock has likely found a bottom. The selloff triggered a buying event and volume spiked to multi‑quarter highs, consistent with institutional accumulation. Institutional data show they own more than 92% of the stock, have been net buyers for six consecutive quarters, and buying activity accelerated in Q1 2026.
That institutional ownership provides a meaningful support base, but with short interest near 7% there is still some downside risk. That level of short interest isn’t extreme, but it can amplify price moves. Even so, the roughly 30% decline following an extended downtrend may present an attractive entry opportunity for investors willing to tolerate near‑term volatility.
Thank you for subscribing to MarketBeat!
MarketBeat empowers everyday investors to make better financial decisions by providing up-to-the-minute financial information and independent investment analysis.
If you have questions about your newsletter, please feel free to contact MarketBeat’s South Dakota based support team at contact@marketbeat.com.
If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails.
Copyright 2006-2026 MarketBeat Media, LLC.
345 N Reid Pl., Suite 620, Sioux Falls, S.D. 57103-7078. United States of America..

